

# 4<sup>th</sup> International Pharma & Clinical Pharmacy Congress

November 07-09, 2016 Las Vegas, Nevada, USA

## Efficiency and safety of combining silybin, lipoteichoic acid and selenomethionine in the treatment of non-alcoholic fatty liver

Daniel Roberto Magdaleno Rodriguez, Avila Lamadrid Pamela Georgina, Sanchez Flores Jessica, Cortes Moreno Gabriela Yanet and Lara Padilla Eleazar  
Instituto Politecnico Nacional, Mexico

Obesity has become a public global health, we cannot lose sight that this disease has reached epidemic global proportions, which is why the World Health Organization (WHO) calls obesity as the epidemic of the century. The purpose of this study was to evaluate the efficacy and safety of the combination of silymarin, selenomethionine and alpha lipoteichoic acid in adult patients with non-alcoholic fatty liver using different dosages, comparing changes in patients receiving doses every 8 hours against the patients that received doses every 12 hours. It was evaluated the biochemical changes through blood, morphological determinations by ultrasound and anthropometric measurements. It was a longitudinal, prospective and comparative study during 12 weeks. This study was conducted under 88 exogenous obese patients, aged between 18 and 60 years of both sexes with Body Mass Index (BMI) between 30 and 45 kg/m<sup>2</sup> and diagnosed with fatty liver confirmed by ultrasound with sub-clinical alterations in liver enzymes. Patients were randomized into two groups of 44 subjects each and were administered for three months the combination of silymarin, selenomethionine and alpha lipoteichoic acid with dosage of one capsule every 8 hours (group 1) and every 12 hours (group 2).

### Biography

Daniel Roberto Magdaleno Rodriguez is currently a Medical student of Superior School of Medicine (Escuela Superior de Medicina) at Instituto Politécnico Nacional, Mexico. He is a Junior Researcher who has been working at the Obesity Center of the School since 2013 on different research lines regarding obesity, diabetes, fatty liver, metabolic syndrome and hypertension. His recent research is focused on drug effectiveness and security for obesity and fatty liver treatment. He is also the CEO and Founder of AIMEDS A.C.

magdalenium@hotmail.com

### Notes: